Advertisement

Topics

Biogen and Sobi Company Profile

22:12 EDT 28th June 2017 | BioPortfolio

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.


News Articles [406 Associated News Articles listed on BioPortfolio]

Sobi - Invitation - Presentation Of Sobi's Q4 And FY 2016 Results

  Life Sciences Jobs   ...

Biogen Acquires Remedy Pharmaceuticals' CIRARA™ for Large Hemispheric Stroke

Phase 3-ready program complements Biogen's ongoing development efforts in stroke Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments Biogen (NASDAQ: BIIB) ...

Sobi secures new deal to combat hemophilia B in Ireland

Stockholm-based biotech firm Swedish Orphan Biovitrum (STO: SOBI) has signed a deal with authorities…

Saudi FDA approves Sobi's Orfadin capsules to treat hereditary tyrosinemia type 1

Swedish Orphan Biovitrum AB (Sobi), has announces that the Saudi Food and Drug Administration (SFDA) has approved Orfadin (nitisinone) capsules in all strengths (2 mg, 5 mg, 10 mg and 20 mg) for the t...

Swedish Orphan Biovitrum AB - Statement Regarding Speculations on a Potential Sale of the Partner Products Business Area

STOCKHOLM, Feb 03, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi') (STO: SOBI) today confirms that the company is in discussions with a private equity firm regarding a possible sal...

Sobi receives SFDA approval for Orfadin capsules

Specialist healthcare company Swedish Orphan Biovitrum (Sobi) has received approval from the Saudi Food and Drug Administration (SFDA) for Orfadin (nitisinone) capsules in strengths of 2mg, 5mg, 10mg ...

Invitation - Presentation of Sobi's Q1 2017 Results

STOCKHOLM, April 13, 2017 /PRNewswire/ -- On 28 April, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2017. Financial analysts and med...

Better Together, or Apart? Biogen, Bioverativ Head Down Separate Paths

Biogen, one of the largest biotechnology companies in the world, was at a crossroads in 2016. An experimental drug for the memory-robbing scourge, Alzheimer’s disease, had shown signs of promise. Th...

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

Avonex [Biogen Idec MA Inc.]

AVONEX (Interferon beta-1a)IM Injection

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Biogen pays Forward in Tecfidera dispute.

A new method for quantifying the performance of EEG blind source separation algorithms by referencing a simultaneously recorded ECoG signal.

Blind source separation (BSS) algorithms extract neural signals from electroencephalography (EEG) data. However, it is difficult to quantify source separation performance because there is no criterion...

The Temporal Dynamics of Response Inhibition and their Modulation by Cognitive Control.

Behavioral adjustments require interactions between distinct modes of cognitive control and response inhibition. Hypothetically, fast and global inhibition is exerted in the reactive control mode, whe...

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

To determine the maximal safe daily dose of BG8962 (rCD4) which can be administered by continuous subcutaneous infusion (CSCI) over 24 hours; to determine the pharmacokinetics of BG8962 wh...

Safety and Tolerability of Repeat Courses of IM Alefacept

Previous Biogen studies have provided experience with the tolerability, immunogenicity, and efficacy of a single and multiple 12-week courses of therapy of alefacept. At this stage, experi...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy

Study phase: Phase II Investigational product, dosage, and route of administration: Ibritumomab tiuxetan ("Zevalin) is composed of a murine IgG1 monoclonal antibody (ibritumomab) covalentl...

Companies [31 Associated Companies listed on BioPortfolio]

Biogen and Sobi

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare ...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the li...

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

More Information about "Biogen and Sobi" on BioPortfolio

We have published hundreds of Biogen and Sobi news stories on BioPortfolio along with dozens of Biogen and Sobi Clinical Trials and PubMed Articles about Biogen and Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biogen and Sobi Companies in our database. You can also find out about relevant Biogen and Sobi Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record